Five decades of human H1N1 evolution reveal conserved glycan receptor specificity
- 1Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Abstract
H1N1 influenza viruses have circulated continuously among human populations for five decades. During evolution, the hemagglutinin has accumulated amino acid substitutions in and around the receptor-binding site (RBS), mainly due to antigenic pressure, potentially altering receptor recognition and binding profiles. Here, we investigated the glycan-binding properties of H1N1 strains collected from 1977 through 2024 using ELISA, flow cytometry, and tissue histochemistry to characterize changes in receptor-binding specificity over time. Across the strains examined, we observe a recurring preference for binding 2,6-sialylated di-LacNAc N-glycans. Binding to 2,3-sialylated glycans was generally undetectable, although A/Hongkong/117/1977 and A/New Caledonia/20/1999 bind chicken tracheal tissues. Interestingly, post-pandemic H1N1 viruses fluctuate in their relative binding avidities. The responsible amino acids, in turn, have different effects in pre-pandemic HA proteins. We also report a classical egg-adapted H1N1 mutant that shows null binding across platforms. These findings highlight the contribution of RBS mutations during initial adaptation and evolution of human H1N1 influenza viruses to glycan-binding properties, which, in contrast to H3N2 viruses, never fail to bind glycans that correlate with avian erythrocyte hemagglutination.
Related
- Beyond seed counts: what two decades of seed testing reveal about European beech in Poland
- Five Decades of Citizen Science Reveal Erosion of Hotspots of Multifaceted Plant Diversity
- Interspecific hybrids reveal a deeply conserved nuclear role of EIF1A-family proteins in zygotic genome activation
- Cnidarian oocytes reveal conserved actin-driven mechanisms of female meiosis
- Single-cell-resolved natural giant virus infections reveal conserved protist immunity
BibTeX
@misc{liang2026five,
title = {{Five decades of human H1N1 evolution reveal conserved glycan receptor specificity}},
author = {R. Liang and J.-W. H. Langenbach and J. Kuo and A. Balas and M. Zobin and G.-J. Boons and R. P. de Vries},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.11.758004},
url = {https://www.biorxiv.org/content/10.64898/2026.10.11.758004v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Five decades of human H1N1 evolution reveal conserved glycan receptor specificity
AU - R. Liang
AU - J.-W. H. Langenbach
AU - J. Kuo
AU - A. Balas
AU - M. Zobin
AU - G.-J. Boons
AU - R. P. de Vries
PY - 2026
DA - 2026/10/11
PB - bioRxiv
DO - 10.64898/2026.10.11.758004
UR - https://www.biorxiv.org/content/10.64898/2026.10.11.758004v1
AB - H1N1 influenza viruses have circulated continuously among human populations for five decades. During evolution, the hemagglutinin has accumulated amino acid substitutions in and around the receptor-binding site (RBS), mainly due to antigenic pressure, potentially altering receptor recognition and binding profiles. Here, we investigated the glycan-binding properties of H1N1 strains collected from 1977 through 2024 using ELISA, flow cytometry, and tissue histochemistry to characterize changes in receptor-binding specificity over time. Across the strains examined, we observe a recurring preference for binding 2,6-sialylated di-LacNAc N-glycans. Binding to 2,3-sialylated glycans was generally undetectable, although A/Hongkong/117/1977 and A/New Caledonia/20/1999 bind chicken tracheal tissues. Interestingly, post-pandemic H1N1 viruses fluctuate in their relative binding avidities. The responsible amino acids, in turn, have different effects in pre-pandemic HA proteins. We also report a classical egg-adapted H1N1 mutant that shows null binding across platforms. These findings highlight the contribution of RBS mutations during initial adaptation and evolution of human H1N1 influenza viruses to glycan-binding properties, which, in contrast to H3N2 viruses, never fail to bind glycans that correlate with avian erythrocyte hemagglutination.
ER -